Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2031625 | 1.00 | LMNA (0.50) | LMNAALDH1A1OR51E2PDE4ACA4 | |
| Glycerin SCHEMBL28637598 | 0.88 | LMNA (0.56) | LMNAALDH1A1OR51E2PDE4ACA4 | |
| Glycerin SCHEMBL4630792 | 0.85 | LMNA (0.60) | LMNAALDH1A1OR51E2CA4SLC22A16 | |
| Glycerin SCHEMBL2938480 | 0.82 | LMNA (0.56) | LMNAALDH1A1OR51E2PDE4ACA4 | |
| Cadaverine Tartrate SCHEMBL630784 | 0.82 | TSHR (0.47) | LMNACA4SLC22A16SLC22A6TSHR | |
| Cadaverine Tartrate SCHEMBL29409197 | 0.82 | TSHR (0.47) | LMNACA4TSHRCYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL29499522 | 0.82 | TSHR (0.47) | LMNACA4TSHRCYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL80796 | 0.82 | TSHR (0.47) | LMNACA4TSHRCYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL5168315 | 0.80 | LMNA (0.46) | LMNAOR51E2PDE4ACA4SLC22A6 | |
| Glycerin SCHEMBL967740 | 0.80 | LMNA (0.53) | LMNAALDH1A1OR51E2CA4SLC22A16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008073490-A1 | PURIFICATION OF INFLUENZA VIRAL ANTIGENS | CARRINGTON LABORATORIES INC., (US) | 2008-06-19 | — | — | WO | claimed |
| EP-2393922-A1 | PURIFICATION OF VIRUS OR VIRAL ANTIGENS BY DENSITY GRADIENT ULTRACENTRIFUGATION | GlaxoSmithKline Biologicals S.A. (BE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110293660-A1 | NOVEL METHOD | ANDRE BRUNO RENE (BE) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089339-A1 | PURIFICATION OF VIRUS OR VIRAL ANTIGENS BY DENSITY GRADIENT ULTRACENTRIFUGATION | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2008073490-A1 | PURIFICATION OF INFLUENZA VIRAL ANTIGENS | CARRINGTON LABORATORIES INC., (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-1829736-A | severe acute respiratory syndrome coronavirus | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-1988001292-A1 | HUMAN ENTERIC CORONAVIRUS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1988-02-25 | — | — | WO | disclosed |